⚠ Evidence warning: Clinical trials or other evidence do not support the claim that a successful transplant fully resolves the classic triad and eliminates the risk of lymphoma. This page keeps it as a report of what people, websites or other media say.

Wiskott-Aldrich Syndrome (WAS)

Few, unusually small platelets in WAS
Few, unusually small platelets in WAS
  1. Overview
  2. The Classic Triad
  3. Disease Spectrum
  4. Complications
  5. Laboratory Findings
  6. Diagnosis
  7. Treatment
  8. Prognosis
  9. Key Research Papers
  10. Connections

Overview

Wiskott-Aldrich Syndrome (WAS) is a rare X-linked primary immunodeficiency disorder characterized by profound immune dysregulation combined with thrombocytopenia (low platelet count with abnormally small platelets). It arises from loss-of-function mutations in the WAS gene located on chromosome Xp11.23, which encodes the Wiskott-Aldrich Syndrome protein (WASp). Because inheritance is X-linked, the disorder affects almost exclusively males, with an incidence given in a 2014 review as approximately one to four cases per 1,000,000 live male births.

WASp is a cytoskeletal regulator expressed exclusively in hematopoietic cells. It acts as a molecular scaffold that links upstream signaling — particularly the small Rho GTPase CDC42 — to downstream actin polymerization via the Arp2/3 complex. When WASp is absent or non-functional, multiple immune-cell lineages fail to perform actin-dependent processes:

The result is a combined B-cell and T-cell immunodeficiency superimposed on bleeding risk, with a significant propensity for autoimmune disease and malignancy in untreated or undertreated patients.

↑ Back to Table of Contents

The Classic Triad

The hallmark of classic Wiskott-Aldrich Syndrome is the simultaneous occurrence of three clinical features that together strongly suggest the diagnosis. Their absence does not rule it out: in a survey of 154 patients, the full classic triad (low platelets with small platelets, recurrent ear infections and eczema) was seen in only 27%, 5% had only infections and 20% had only blood findings before diagnosis, and the authors concluded that many patients have an atypical presentation and often need a panel of tests.

1. Thrombocytopenia with Microplatelets

The platelet abnormality in WAS is unique and diagnostically important. Unlike immune thrombocytopenic purpura (ITP), where the immune system destroys normal or large platelets, in WAS the platelets are intrinsically abnormal — they are small (low mean platelet volume, MPV) as well as reduced in number. Platelet counts typically range from 20,000 to 50,000/µL (normal 150,000–400,000/µL). The low MPV is a key distinguishing laboratory feature from ITP, where MPV is normal or elevated.

Bleeding manifestations include:

2. Eczema

Atopic dermatitis in WAS is often severe and begins in early infancy, frequently as the first or most prominent feature. The eczema can be indistinguishable from severe atopic dermatitis of other causes but is characteristically refractory to standard topical therapies and prone to superinfection, particularly with Staphylococcus aureus and Herpes simplex virus, which causes the widespread skin infection called eczema herpeticum. It is driven by dysregulated Th2 skewing and elevated immunoglobulin E (IgE), reflecting the underlying immune imbalance.

3. Recurrent Infections

WAS produces a combined humoral and cellular immunodeficiency. The antibody deficiency is selective but clinically significant — patients have a characteristically poor response to T-independent type 2 antigens (polysaccharide capsule components), making them uniquely vulnerable to encapsulated organisms:

Viral susceptibility is also elevated, particularly to herpesviruses:

Opportunistic infections (Pneumocystis jirovecii pneumonia, fungal infections) occur particularly in patients with severe WASp deficiency.

↑ Back to Table of Contents

Disease Spectrum

WAS is not a single uniform phenotype. Depending on the nature of the WAS gene mutation and residual WASp function, the clinical picture spans a wide spectrum. A clinical severity score (WAS score 1–5) is widely used:

A 2025 expert review recommends discontinuing the term X-linked thrombocytopenia “as it implies a mild and uncomplicated disease, which is not the norm”, and describing each patient by genetic profile, disease severity and clinical course instead.

Female Carriers

Female carriers of WAS mutations are typically asymptomatic due to preferential X-inactivation that silences the mutant allele in hematopoietic cells. However, in carriers with unfavorable (non-skewed) X-inactivation, mild thrombocytopenia may occur. Rarely, a female with Turner syndrome (45,X) or compound heterozygosity can be fully affected.

X-Linked Neutropenia (XLN)

A distinct gain-of-function mutation in the GBD domain of WAS (L270P and I294T alleles) causes X-linked neutropenia with myelodysplasia, without thrombocytopenia — the opposite end of the WASp dysfunction spectrum. This underscores the role of WASp in myeloid lineage regulation beyond just immune cells and platelets.

↑ Back to Table of Contents

Complications

Untreated or undertreated Wiskott-Aldrich Syndrome carries four major categories of life-threatening or debilitating complications:

Bleeding

Intracranial hemorrhage (ICH) is the most feared acute complication and was historically the most common cause of early death. Even minor head trauma can precipitate ICH in a child with a platelet count of 20,000–30,000/µL. Gastrointestinal bleeding, epistaxis, and bleeding after dental procedures or surgery are also significant risks throughout life.

Infections

Severe, recurrent bacterial infections — particularly meningitis and bacteremia from encapsulated organisms — were the second major cause of death in the pre-IVIG and pre-HSCT era. Opportunistic infections (Pneumocystis pneumonia, cryptococcal meningitis, disseminated cytomegalovirus) occur in patients with significant T-cell dysfunction. Epstein-Barr virus-driven lymphoproliferative disease bridges the infection and malignancy categories.

Malignancy

WAS patients face a 20- to 22-fold increased risk of malignancy compared with the general population. The vast majority are lymphomas, predominantly Epstein-Barr virus-driven non-Hodgkin B-cell lymphomas (Burkitt-like, diffuse large B-cell). Leukemia and other hematologic malignancies also occur. Malignancy can begin in childhood: a survey reported in a 2014 review found that 13% of patients developed malignancy at a mean age of 9.5 years. Its risk is described as substantially eliminated by successful HSCT, although the same review estimates malignancy after transplant at 3.3% in WAS.

Autoimmunity (Paradoxical)

Approximately 40% of WAS patients develop significant autoimmune disease — a counterintuitive finding given the underlying immunodeficiency. The mechanism is Treg dysfunction: WASp-deficient regulatory T cells fail to adequately suppress autoreactive clones. Manifestations include:

The coexistence of autoimmunity worsens prognosis and increases the urgency of definitive HSCT.

↑ Back to Table of Contents

Laboratory Findings

The laboratory profile of WAS is distinctive and, when the full pattern is recognized, strongly supports the diagnosis before molecular confirmation:

↑ Back to Table of Contents

Diagnosis

The diagnosis of WAS comes into question in any male infant or child presenting with:

Stepwise Diagnostic Approach

  1. Complete blood count (CBC) with differential and smear: Confirms the low platelet count and shows platelet size and shape. Automated MPV is the fastest clue — a low MPV in a male with a low platelet count raises strong suspicion of WAS.
  2. Immunoglobulin quantification: immunoglobulin G, immunoglobulin A, immunoglobulin M, immunoglobulin E levels.
  3. Vaccine antibody titers: Responses to both protein (tetanus, diphtheria) and polysaccharide (pneumococcal) antigens are measured; selective polysaccharide unresponsiveness is highly characteristic.
  4. WASp protein expression by intracellular flow cytometry: The pivotal screening test. Absent or markedly reduced WASp in PBMCs confirms significant WAS gene dysfunction. A small percentage of patients with missense mutations produce a non-functional but detectable WASp; flow cytometry may be normal or near-normal in these cases.
  5. WAS gene sequencing: Definitive confirmation and guides family counseling and prenatal testing. Next-generation sequencing panels covering the full coding sequence and splice sites are available in most reference laboratories.

Differential Diagnosis

Prenatal and Carrier Diagnosis

When the family mutation is known, prenatal diagnosis by chorionic villus sampling (CVS) or amniocentesis is available. Carrier testing of at-risk female relatives by WAS gene sequencing allows family planning and preparation for an affected pregnancy.

↑ Back to Table of Contents

Treatment

Management of WAS is stratified by disease severity and the availability of a suitable hematopoietic stem cell transplant (HSCT) donor. For all patients, supportive measures begin immediately at diagnosis.

Supportive and Prophylactic Therapy

Hematopoietic Stem Cell Transplantation (HSCT) — Curative

HSCT has historically been the only proven curative therapy for WAS. It replaces the patient's defective hematopoietic system with donor-derived cells that carry a functional WAS gene, correcting all three arms of the classic triad — thrombocytopenia, immune deficiency, and (over time) eczema.

Gene Therapy

Lentiviral vector-based gene therapy has emerged as a curative alternative for patients lacking a matched donor. The autologous approach — transducing the patient's own hematopoietic stem cells with a functional WAS cDNA under control of the endogenous WAS promoter — avoids GVHD entirely. The therapy, etuvetidigene autotemcel (research code OTL-103), was developed by a foundation, Fondazione Telethon, with the San Raffaele Telethon Institute for Gene Therapy (Milan). Trials of lentiviral gene therapy have shown:

Why Lentiviral Vectors Replaced the Earlier Ones

An earlier gene therapy trial in WAS used a gammaretroviral vector. It worked in 9 of 10 patients, with lasting correction of the protein and partial or complete resolution of immune deficiency, autoimmunity and bleeding, but 7 of the 10 developed acute leukemia because the vector had inserted near cancer-related genes such as LMO2. The authors concluded that this vector carries a substantial risk of leukemia. A 2026 review describes this as the reason the field moved to self-inactivating lentiviral vectors, and reports no cases of vector-related leukemia with them.

Splenectomy

Splenectomy significantly raises platelet counts (by removing the primary site of platelet destruction) but substantially increases the risk of overwhelming post-splenectomy sepsis with encapsulated organisms. In a patient who already has impaired polysaccharide antibody responses, this risk is amplified. A study of 173 patients with the milder form found that splenectomy increased the risk of severe infections. Splenectomy is generally avoided as definitive management and is not used before or instead of HSCT workup.

↑ Back to Table of Contents

Prognosis

The prognosis of WAS has been transformed by HSCT and, more recently, gene therapy. The natural history — without curative treatment — is poor:

With modern treatment:

Early diagnosis remains the most modifiable prognostic factor. Newborn screening programs using next-generation sequencing (NGS) panels — or screening for T-cell receptor excision circles (TREC) and kappa-deleting recombination excision circles (KREC) extended to WAS — have the potential to identify affected boys before their first serious complication, enabling early transplantation and optimal outcomes.

↑ Back to Table of Contents

Key Research Papers

The following peer-reviewed publications represent foundational and landmark research in the understanding and treatment of Wiskott-Aldrich Syndrome:

  1. Derry JM, Ochs HD, Francke U. (1994). Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 78(4):635–644. — PubMed PMID: 8069912
  2. Symons M, Derry JM, Karlak B, et al. (1996). Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 84(5):723–734. — PubMed PMID: 8625410
  3. Snapper SB, Rosen FS. (1999). The Wiskott-Aldrich syndrome protein (WASp): roles in signaling and cytoskeletal organization. Annual Review of Immunology. 17:905–929. — PubMed PMID: 10358777
  4. Filipovich AH, Stone JV, Tomany SC, et al. (2001). Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 97(6):1598–1603. — PubMed PMID: 11238097
  5. Imai K, Morio T, Zhu Y, et al. (2004). Clinical course of patients with WASP gene mutations. Blood. 103(2):456–464. — PubMed PMID: 12969986
  6. Aiuti A, Biasco L, Scaramuzza S, et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 341(6148):1233151. — PubMed PMID: 23845947
  7. Moratto D, Giliani S, Bonfim C, et al. (2011). Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 118(6):1675–1684. — PubMed PMID: 21659547
  8. Massaad MJ, Ramesh N, Geha RS. (2013). Wiskott-Aldrich syndrome: a comprehensive review. Annals of the New York Academy of Sciences. 1285:26–43. — PubMed PMID: 23527602
  9. Humblet-Baron S, Sather B, Anover S, et al. (2007). Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. Journal of Clinical Investigation. 117(2):407–418. — PubMed PMID: 17218989
  10. Braun CJ, Boztug K, Paruzynski A, et al. (2014). Gene therapy for Wiskott-Aldrich Syndrome — long-term efficacy and genotoxicity. Science Translational Medicine. 6(227):227ra33. — PubMed PMID: 24622513
  11. Puck JM, Candotti F. (2006). Lessons from the Wiskott-Aldrich syndrome. New England Journal of Medicine. 355(17):1759–1761. — PubMed PMID: 17065636
  12. Ochs HD, Thrasher AJ. (2006). The Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology. 117(4):725–738. — PubMed PMID: 16630926
  13. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. (1994). A multiinstitutional survey of the Wiskott-Aldrich syndrome. Journal of Pediatrics. 125(6 Pt 1):876–885. — PubMed PMID: 7996359
  14. Albert MH, Bittner TC, Nonoyama S, et al. (2010). X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 115(16):3231–3238. — PubMed PMID: 20173115
  15. Buchbinder D, Nugent DJ, Fillipovich AH. (2014). Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Application of Clinical Genetics. 7:55–66. — PubMed PMID: 24817816
  16. Ferrua F, Cicalese MP, Galimberti S, et al. (2019). Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematology. 6(5):e239–e253. — PubMed PMID: 30981783
  17. Magnani A, Semeraro M, Adam F, et al. (2022). Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome. Nature Medicine. 28(1):71–80. — PubMed PMID: 35075289
  18. Vallée TC, Albert MH, Pai SY. (2025). How I treat Wiskott-Aldrich syndrome. Blood. 146(1):41–51. — PubMed PMID: 40209058
  19. Soresina A, Rondelli R, Notarangelo LD, et al. (2025). Long-term outcome in Wiskott-Aldrich syndrome and X-linked thrombocytopenia patients: an observational -prospective multi-center study of the Italian Primary Immune Deficiency Network (IPINET). EClinicalMedicine. 84:103271. — PubMed PMID: 40547444
  20. Blair HA. (2026). Etuvetidigene Autotemcel: First Approval. Molecular Diagnosis & Therapy. 30(3):539–543. — PubMed PMID: 41882319
  21. Ferrua F, Cenciarelli S, Giannelli S, et al. (2026). Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome. New England Journal of Medicine. 395(12):1193–1205. — PubMed PMID: 42777242
  22. Karimizadeh Z, Kalantari A, Behfar M, et al. (2026). From oncogenesis to approval: the lentiviral gene therapy revolution in Wiskott-Aldrich syndrome. Regenerative Medicine. 21(8-9):519–528. — PubMed PMID: 42856044

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents